Matthew Moll is a Respiratory physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
72 E Concord St
Evans 124
Boston, MA 021182307
Telephone
617-638-6551Registry record last updated 2 Jul 2019.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year20251 payment
- Verona Pharma, Inc.Program year20251 payment
- SANOFI US SERVICES INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
82%Corticosteroid46.7%Trelegy Ellipta43%Symbicort30%Fluticasone Propionate17%Breztri Aerosphere9%Part D<11 patientsbeta2-Adrenergic Agonist17.2%Ventolin Hfa67%Albuterol Sulfate Hfa33%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
11.9%Corticosteroid6.9%Prednisone100%Part D≥12 patientsProton pump inhibitor5%Omeprazole100%Part D<11 patientsDermatology
6.1%Interleukin-4 Receptor alpha Antagonist6.1%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Integrating Multi-Trait Genetics, Proteomics, and Deep Learning to Uncover Biomarkers and Therapeutic Targets for COPD Exacerbations
Brigham and Women'S Hospital
FY2026$894,314R01HL185567 - Network Proximity-based Drug Repurposing in COPD
Brigham and Women'S Hospital
FY2026$372,635R21HL188684 - Multi-omic Risk Prediction of Chronic Obstructive Pulmonary Disease in European- and African-Ancestry Populations
Brigham and Women'S Hospital
FY2026$168,480K08HL159318
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”